Skip to main content
. Author manuscript; available in PMC: 2016 Mar 1.
Published in final edited form as: J Allergy Clin Immunol. 2014 Aug 28;135(3):701–709.e5. doi: 10.1016/j.jaci.2014.06.038

Table VI.

Asthma symptoms, lung function and sinus symptoms in adults (ages 18 and older) treated with mometasone versus placebo.

Treatment Assignment Rate Ratio
(95% CI)*
Mometasome / Placebo
P-value*
Mometasone
(N = 111)
Placebo
(N = 111)

Episodes of poor asthma control, overall
  Patients with ≥ 1 event, N (%) 45 (41%) 48 (43%)
  Number of events 104 114
  Annual per-person event rate (95% CI) 2.5 (1.9, 3.5) 2.6 (1.9, 3.5) 0.98 (0.64, 1.51) 0.92
Episodes of poor asthma control, components
Drop in peak flow of30 % for 2 consecutive days
  Patients with ≥ 1 event, N (%) 14 (21%) 20 (27%)
  Number of events 38 68
  Annual per-person event rate (95% CI) 0.9 (0.5, 1.5) 1.7 (1.1, 2.6) 0.55 (0.27, 1.10) 0.09
Urgent asthma care
  Patients with ≥ 1 event, N (%) 6 (5%) 11 (9%)
  Number of events 6 14
  Annual per-person event rate (95% CI) 0.1 (0.1, 0.3) 0.3 (0.2, 0.6) 0.45 (0.16, 1.27) 0.13
Systemic steroids
  Patients with ≥ 1 event, N (%) 15 (14%) 17 (15%)
  Number of events 20 15
  Annual per-person event rate (95% CI) 0.3 (0.2, 0.5) 0.4 (0.3, 0.7) 0.78 (0.40, 1.52) 0.47
Increased Rescue Medications
  Patients with ≥ 1 event, N (%) 29 (28%) 27 (26%)
  Number of events 62 49
  Annual per-person event rate (95% CI) 1.7 (1.1, 2.5) 1.2 (0.8, 1.9) 1.42 (0.78, 2.59) 0.25
*

Rate Ratios, 95% Confidence Intervals (CIs) and p-values are based on negative binomial regression.

HHS Vulnerability Disclosure